ALAMEDA,
Calif., April 25, 2024 /PRNewswire/ -- CellFE
Inc., a life sciences tools company with a novel
microfluidics-based cellular engineering platform, announced
today an upcoming presentation by CSO Todd Sulchek, PhD, at
the American Society of Gene and Cell Therapy (ASGCT) Annual
Meeting, taking place May 7-11, 2024
in Baltimore, MD. The company will
also present an accepted abstract showcasing the company's
microfluidic approach for high efficiency CRISPR/Cas9 knockout via
sequential editing.
"We are excited to return to ASGCT this year and present
new data that validates the advantage of our microfluidic
technology in enabling rapid sequential editing with superior
viability and transfection efficiencies," said Dr. Sulchek. "By
unlocking this sequential editing process for complex payloads, our
technology delivers high yields of edited cells with reduced risk
of genomic translocations – currently a key roadblock for cell
therapy manufacturers."
Sponsor Presentation Details:
Title: A Novel,
Microfluidics Approach to Advance Innovative Cell Therapy
Manufacturing, Todd Sulchek, PhD
Session Title: Tools and Technology Forum 6
Date and Time: Friday, May 10,
2024, 3:45 p.m. – 4 p.m. ET
Location: Exhibit Hall Theater
Poster Presentation Details:
Title: Multiplex
CRISPR/Cas9 Knockout Utilizing Sequential Delivery via
Microfluidics Transfection System, Melis
Keceli
Session: Other Nonviral Delivery
Abstract Number: 756
Date and Time: Wednesday, May 8, 2024, 12 p.m. ET
Location: Exhibit Hall
CellFE will be exhibiting at Booth #828 at ASGCT from
May 7-11th in Baltimore, MD. Abstracts are available to the
public at https://annualmeeting.asgct.org/. A copy of the sponsor
presentation and abstract will be available at
www.cellfebiotech.com after the conference concludes.
About CellFE Inc.
CellFE, a cutting-edge microfluidics
company, is transforming the development and manufacturing of
lifesaving cell therapies to make them more accessible to patients.
The Company's microfluidic-based cell engineering platform offers
complex editing with reduced risk of translocation events,
streamlined scalability, and rapid workflows. Benefits of the
CellFE platform include superior cell health and yield with reduced
expansion times, drastically minimizing both vein-to-vein times and
enabling more robust and durable therapies. By limiting the need
for specialized buffers, the technology ensures optimization is
directly transferrable from low to high volumes, so cell therapy
developers can seamlessly scale from research to clinical and
beyond. CellFE is committed to enabling their partners' success
through close collaborations designed to solve the challenges
associated with the development and manufacturing of
next-generation cell therapies.
https://www.cellfebiotech.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cellfe-announces-may-2024-conference-presentations-302127872.html
SOURCE CellFE